Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.
about
Molecular and therapeutic potential and toxicity of valproic acidUp-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acidEpigenetic modulators as therapeutic targets in prostate cancerHydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trialA reproducible approach to high-throughput biological data acquisition and integrationInverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases.A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.Response to hydralazine-valproate in a patient with mycosis fungoidesThe Effect of Sodium Valproate on the Glioblastoma U87 Cell Line Tumor Development on the Chicken Embryo Chorioallantoic Membrane and on EZH2 and p53 Expression.Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor proteinAcyl-coenzyme A binding domain containing 3 (ACBD3; PAP7; GCP60): an emerging signaling molecule.A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group reportInduction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney DiseaseA genomic approach to predict synergistic combinations for breast cancer treatmentThe effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical studyBrain tumor-related epilepsy.Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitroRecent advances in the search for antiviral agents against human papillomaviruses.Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylationA Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers.Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model.Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.The application of delivery systems for DNA methyltransferase inhibitors.Epigenetic-based therapies in cancer: progress to date.Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment.Emerging drugs for cervical cancer.Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.Emerging drugs for the treatment of cervical cancer.Anti-neoplastic properties of hydralazine in prostate cancer.Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine.Hydralazine target: from blood vessels to the epigenome.Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.Lecture: profile of risks and benefits of new antiepileptic drugs in brain tumor-related epilepsy.The pharmacogenomics of valproic acid.
P2860
Q21296867-3436FE84-3D69-4780-B84D-FC9C1C28B28CQ24288944-EA0ECBAE-F8A3-4183-B045-49130ACDAE04Q28071912-DA9647B8-A7EA-44D2-BB3F-7C699B297EB5Q28294892-E1F917D7-F94C-42A5-ACF7-4CCA173375EDQ28647460-25284C97-9DD3-4078-934B-E9B46D221AE2Q31040399-2935B792-EE06-488A-BC54-05AB8C982354Q33267359-A2095A88-0BA3-4804-A429-3C5A686A3971Q33420263-43023569-6311-4B46-ACEF-FC7A16D7E278Q33743913-5A1FE07A-CC4F-470D-985D-106A4AB25196Q33794860-63214BF3-CFE6-4681-820F-D7E7F5A2BD6FQ33796184-557FB227-CC91-4651-B5B5-F67C679EE31FQ33862407-68726F88-73A3-4D02-8BD6-9523A4146EC1Q34142430-5ABC38AD-F7F2-4768-B8BA-2C311EFDA2BDQ34722045-4AB039C8-FBEC-44F0-AA1F-9D869669459CQ35110633-18B4A2D3-13BD-413F-8447-5D2C419A8C2DQ35670293-BB72447F-3242-4379-88F0-853B1C92ED5BQ35674823-0298610C-4196-40E0-99AE-E83476B28387Q36067319-312C4F89-B8C5-4CEF-9842-3EB29A713D10Q36230522-90584B92-AB09-44FB-AA98-C7D57314F6BDQ36284493-2167ECDD-FE6E-47D6-831E-9EC61C48C6A0Q36335796-C434114E-F983-48EF-B0F0-57450CDF0C19Q36689831-8F31A063-5ED3-4C7F-AF46-70C919A6A033Q37171078-5F38CB9B-0922-4844-BAFC-1688F68B80C2Q37472163-E66943CD-E708-4FC3-99BB-5A350E8F6B4CQ37716414-58EB7C69-EA89-4382-961C-9B80AC4A3C25Q37911496-B0BA7E59-A8F4-4785-9B8E-9E096F49F516Q37964702-F90E99A5-F798-4BC2-B4D5-A3D3BBA3AD62Q37968607-E1992E07-9E86-4634-9D6A-510434948BA7Q38005222-FF1DF2B0-CE82-4841-9B17-6A00B7B6BA11Q38242979-3EE7E543-1D7C-40C3-AA7B-9B54633340BBQ38314157-0DFE5E58-EE97-49BF-95DB-9BD259B1FE9CQ38998403-F5DCDBAF-1EB1-4152-92FC-9A690D6C4CE3Q39220891-9C648606-FFF4-49F6-B59F-014E786DB80FQ39610375-7014E11D-CA19-498B-8AD0-A333C15FBA0AQ42584531-ED8EDDF7-A355-45F5-ADDD-57DDE64B9C75Q43150766-B030CCFE-5806-4E55-926E-B6EB48EC60A5Q43251030-D0FE50B0-2870-46B0-9EFD-94BEA5B169BCQ47949323-FFEB6944-8CAA-4B30-8E8A-D982C452F062Q48536808-1BF45F8E-6DF2-4EF7-99EB-6F610A4C062DQ50212278-07D1A5AE-5F06-489C-A491-07EB44DFEFAD
P2860
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Antineoplastic effects of the ...... roic acid in cancer cell lines
@nl
Antineoplastic effects of the ...... oic acid in cancer cell lines.
@ast
Antineoplastic effects of the ...... oic acid in cancer cell lines.
@en
type
label
Antineoplastic effects of the ...... roic acid in cancer cell lines
@nl
Antineoplastic effects of the ...... oic acid in cancer cell lines.
@ast
Antineoplastic effects of the ...... oic acid in cancer cell lines.
@en
prefLabel
Antineoplastic effects of the ...... roic acid in cancer cell lines
@nl
Antineoplastic effects of the ...... oic acid in cancer cell lines.
@ast
Antineoplastic effects of the ...... oic acid in cancer cell lines.
@en
P2093
P2860
P356
P1476
Antineoplastic effects of the ...... oic acid in cancer cell lines.
@en
P2093
Alfonso Duenas-Gonzalez
Alma Chavez-Blanco
Aurora Gonzalez-Fierro
Blanca Segura-Pacheco
Carlos Perez-Plasencia
Catalina Trejo-Becerril
Claudia Carrasco-Legleu
Edgar Rangel-Lopez
Enrique Perez-Cardenas
Gustavo Cabrera
P2860
P2888
P356
10.1186/1475-2867-6-2
P407
P577
2006-01-31T00:00:00Z
P5875
P6179
1024823368